ASPHO Webinars Offer Convenient, On-Demand Educational Opportunities
ASPHO webinars are free non-CME presentations led by experts in clinical and career topics of broad interest to our members. Webinar attendees can participate live and ask presenters and moderators questions, or they can watch a recorded version after the event.
2019-2020 Webinar Series
Tuesday, September 17 at 3 pm CST
Pediatric Sickle Cell Disease: Improving Care in the ED
Emergency department care for children with sickle cell disease is highly variable and many health systems have difficulty treating acute severe pain within 30 minutes of triage and 60 minutes of arrival as recommended in national guidelines. Similar delays are seen in the evaluation and treatment of fever. This webinar will describe the barriers to rapid assessment and treatment and strategies to overcome them. The speakers will highlight two effective partnerships for quality improvement initiatives and the positive outcomes associated with decreased time to effective treatment. Participants will use this information to partner with the ED to improve SCD care.
- Describe guidelines for the emergency evaluation and treatment of pain and fever in children with sickle cell disease
- Communicate effective approaches for partnership with emergency department providers, nurses, and administrators to improve care
- Describe outcomes of quality improvement initiatives in the emergency department to improve the care of children with sickle cell disease
John Strouse, MD PhD
Patricia Kavanagh MD
Jennifer Rothman, MD
Wednesday, October 30 at 3 pm CST
Harnessing Diversity to Improve Outcomes for Children with Blood Disorders and Cancer
In the US, children of minority racial/ethnic backgrounds with acute lymphoblastic leukemia have worse outcomes than non-minority children. Children and adults with sickle cell disease face barriers to medication adherence and difficulty obtaining acute and chronic care. Individuals with sickle trait may not be provided appropriate genetic counseling information. In this webinar, we propose to discuss how increasing understanding of diversity in the medical setting can help identify and mitigate barriers to care, in turn improving outcomes for children of minority backgrounds with hemoglobinopathies and cancer.
- Explore cultural/racial barriers to optimal clinical care, genetic counseling, and medication adherence for children with blood disorders and cancer
- Identify the impact of increasing diversity of local care teams on patient outcomes
- Discuss strategies for increasing diversity within the care team
Monica Hulbert, MD
Washington University School of Medicine
Kira Bona, MD MPH
Boston Children's Hospital/Harvard Medical School
Emily Meier, MD MSHS
Indiana Hemophilia and Thrombosis Center
Leticia Brown, MPH
Community Health Workers
Wednesday, December 4 at 3 pm CST
Brain Tumors and Related Therapies
Pediatric central nervous system tumors are the leading cause of cancer-related deaths among children and young adults. For children aged 0-19 years, average survival rate is 75%. There is an urgent need for novel biologically driven therapies for these children since majority of the children fail or do not respond adequately to conventional or high-dose chemotherapy, and radiation therapy through the creation of brain tumor-focused consortiums, participating centers are more rapidly able to conduct clinical phase I and II trials for evaluation of new and molecularly targeted therapeutic agents. In recent years, immunotherapies have also proven to be relevant for treatment of refractory or relapsed leukemias, lymphomas, and solid tumors. These novel therapies are now being evaluated in certain subtypes of pediatric brain tumors.
This webinar is aimed to educate general hematologists/oncologists on current consortiums and elaborate on some novel therapeutics undergoing early phase clinical evaluation. Specific overviews of therapies relevant for low-grade gliomas, ependymomas, and atypical teratoid rhabdoid tumors will be highlighted.
- Identify existing pediatric neuro-oncology consortiums (COG, CONNECT, PNOC, CERN, PBTC, CBTTC)
- Describe current molecularly targeted agents for central nervous system tumors, (i.e., Vismodegib, BRAF agents, Alisertib, and Tazemostat
- Describe current immunotherapies available for central nervous system tumors (i.e., chimeric antigen receptor (CAR) T-cell immunotherapy, vaccine therapies)
- Outline current treatment strategies for low-grade gliomas including standard of care agents and molecularly targeted therapies
- Outline current treatment strategies for ependymomas including standard of care and current clinical trials
- Outline current treatment strategies for atypical teratoid rhabdoid tumor, including recent and ongoing clinical trials
Cathleen Cook, MD MEd FAAP
East Carolina University, Brody School of Medicine
Santhosh A. Upadhyaya, MD
St. Jude Children's Research Hospital
Lindsey Hoffman, DO, MS
Phoenix Children’s Hospital
Daniel Landi, MD
Preston Robert Tisch Brain Tumor Center
Tuesday, February 25 at 3 pm CST
Updates and Advances in Bone Marrow Failure Syndrome
Chandrika Gowda, MD
Penn State Children’s Hospital
Elissa Furutani, MD
Dana Farber/Boston Children’s Hospital
Akiko Shimamura, MD PhD
Dana Farber/Boston Children’s Hospital
Tuesday, March 24 at 3 pm CST
Evaluation and Management of Non-Pain Symptoms
Many hematology-oncology providers are comfortable with pain management but may not feel as comfortable or competent with non-pain symptom management, especially when front-line options fail or prior training has not covered additional options. This webinar will cover pharmacologic and non-pharmacologic management options for non-pain symptoms, such as nausea, constipation, dyspnea, anxiety and fatigue. Pediatric Palliative Oncology specialists will discuss assessment and management of non-pain symptoms, providing knowledge that participants can apply to their patients. Through this improved comfort it is hoped that patients will have improved quality of life.
- Assess for non-pain symptoms, such as nausea, dyspnea, anxiety, or fatigue, which may not be fully appreciated.
- Identify underlying causes for non-pain symptoms.
- Outline evidence-based treatment strategies for nausea/vomiting, dyspnea, anxiety, and fatigue that include non-pharmacological and pharmacological therapies.
Julienne Brackett, MD
Baylor College of Medicine/Texas Children's Cancer and Hematology Centers
Katharine Brock, MD
Emory/Children's Healthcare of Atlanta
Justin Baker, MD
St. Jude Children’s Research Hospital
Thursday, April 30 at 12 pm CST
Uterine Hemostasis and Menstrual Management in the Adolescent: A Multidisciplinary Approach
Heavy menstrual bleeding at menarche and in the early gynecologic years is often attributed to anovulation. While anovulation can cause heavy bleeding, other etiologies such as bleeding disorders (BD), should be considered. This webinar, relevant to pediatric hematology/oncology clinicians, will discuss the diagnosis and management of bleeding disorders.
- Gather basic information about menstrual cycles that is critical in assessing an adolescent's menstrual bleeding and recognize red flags that suggest an underlying bleeding disorder
- Order and interpret appropriate labs to assess the hypothalamic-pituitary-ovarian axis and underlying bleeding disorders in adolescents with heavy menstrual bleeding
- Discuss management considerations for adolescents with heavy menstrual bleeding and bleeding disorders
Mukta Sharma, MD MPH
Children’s Mercy, University of Missouri Kansas City
Paula J. Hillard, MD
Stanford University School of Medicine
Ayesha Zia, MD
University of Texas Southwestern Medical Center
*Webinars are 30-minute presentations followed by 15 minutes for questions and answers. The material presented in these activities represents the opinion of the speaker(s) and not necessarily the views of ASPHO.
Recordings of all webinars can be accessed through the Knowledge Center.